
Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of TreatmentCorrection
JAMA. 2003;290:756.
Incorrect Sentence: In the Original Contribution entitled "Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment" published in the April 2, 2003, issue of THE JOURNAL (2003;289:1645-1651), there was an incorrect sentence on pages 1646 and 1647. The sentence that read "Ninety-six (32%) patients never received hydroxyurea; 48 (16%) received hydroxyurea for less than year and 156 (52%) received hydroxyurea for 1 or more years" should have read "Thirty-two percent of patients randomly assigned to placebo never received hydroxyurea; 16% received hydroxyurea for less than 1 year and 52% received hydroxyurea for one or more years."
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Can Homeopathy Bring Additional Benefits to Thalassemic Patients on Hydroxyurea Therapy? Encouraging Results of a Preliminary Study
Banerjee et al.
Evid Based Complement Alternat Med 2007;0:nem161v1-nem161.
ABSTRACT
| FULL TEXT
|